Cost-effectiveness of a transvalvular microaxial flow pump in infarct-related cardiogenic shock from the perspective of German statutory health insurance
Expert Review of Pharmacoeconomics & Outcomes Research · 18.11.2026
DOI: 10.1080/14737167.2026.2767331 ↗Kurz gefasst
Fachartikel in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, online erschienen am 18.11.2026. Verfasst von Priyanka Boettger und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine I, Cardiology, Angiology and Intensive Care Medicine, Justus Liebig University, Giessen, Germany. Die Arbeit nennt 29 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: In infarct-related cardiogenic shock, a transvalvular microaxial flow pump reduced 180 day mortality but increased adverse events. We evaluated its cost-effectiveness for German statutory health insurance (SHI). RESEARCH DESIGN AND METHODS: A cohort state-transition model compared the two strategies over a lifetime horizon: a 180 day acute phase from trial outcomes, and chronic states with or without heart failure. Costs and quality-adjusted life-years (QALYs) were discounted at 3% in 2023 euros. Parameter uncertainty was assessed probabilistically and unresolved acute payments by threshold analysis. RESULTS: The pump yielded 1.06 additional QALYs at incremental costs of €38,121 and an incremental cost-effectiveness ratio of €36,083 per QALY. At an illustrative willingness-to-pay threshold of €50,000 per QALY, the probability of cost-effectiveness was 86%. Bleeding 21.8 versus 11.9%, limb ischemia 5.6 versus 1.1%. Due to the lack of arm-specific case-group data, the reference analysis assumed no between-arm difference in acute payments; net monetary benefit (NMB) remained positive below €14,703. CONCLUSIONS: Under the reference assumptions, the pump may be cost-effective for German SHI, conditional on an unresolved acute payment difference in which arm-specific routine billing data could be determined. CLINICAL TRIAL REGISTRATION: https://www.clinicaltrials.gov identifier: NCT01633502. This economic analysis was not performed separately.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine I, Cardiology, Angiology and Intensive Care Medicine, Justus Liebig University, Giessen, Germany.
- Department of Health Policy, London School of Economics and Political Science, London, UK.
- Cardio-Pulmonary Institute, Giessen, Germany.
- Department of Internal Medicine II, Heart Center Suedwestfalen, Cardiology, Angiology and Intensive Care Medicine, St. Marien-Krankenhaus, Siegen, Germany.
- Hamburg Center for Health Economics, University of Hamburg, Hamburg, Germany.
- Faculty of Economics, Business Informatics and Business Law, University of Siegen, Siegen, Germany.
ORCID-Profile: Priyanka Boettger
Zitieren
APA
Boettger, P., Sossalla, S., Buerke, M., Birkner, B., & Wild, E. M. (2026). Cost-effectiveness of a transvalvular microaxial flow pump in infarct-related cardiogenic shock from the perspective of German statutory health insurance. Expert Review of Pharmacoeconomics & Outcomes Research. https://doi.org/10.1080/14737167.2026.2767331
Vancouver
Boettger P, Sossalla S, Buerke M, Birkner B, Wild EM. Cost-effectiveness of a transvalvular microaxial flow pump in infarct-related cardiogenic shock from the perspective of German statutory health insurance. Expert Review of Pharmacoeconomics & Outcomes Research. 2026. doi:10.1080/14737167.2026.2767331
BibTeX
@article{Boettger2026,
author = {Boettger, Priyanka and Sossalla, Samuel and Buerke, Michael and Birkner, Benjamin and Wild, Eva-Maria},
title = {Cost-effectiveness of a transvalvular microaxial flow pump in infarct-related cardiogenic shock from the perspective of German statutory health insurance},
journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
year = {2026},
doi = {10.1080/14737167.2026.2767331}
}
EUVIMED